Changes to certain s100 programs

Page last updated: 23 January 2020

On 1 January 2020, changes were made to the Pharmaceutical Benefits Scheme (PBS) restrictions for growth hormone treatment in adults, which set out the eligibility requirements for PBS subsidy, to provide additional clarity and improved access to growth hormone treatment. The following Frequently Asked Questions document provides information about the growth hormone program:

On 1 February 2019, revised eligibility restrictions to PBS subsidised paediatric growth hormone treatment took effect. The eligibility restriction changes relate to:

  • revised height percentile thresholds;
  • growth velocity percentile for bone age and sex;
  • clarification of definitions within the restrictions; and
  • streamlining the way associated growth data requirements are specified within the prescriber instructions.

Since 2015, changes have been made to certain Section 100 (s100) programs under the PBS.  These changes, which include the introduction of community access arrangements for a number of medicines available under the Highly Specialised Drugs Program, are recommended by the Pharmaceutical Benefits Advisory Committee. The Frequently Asked Questions documents below outline the changes made and have been developed to assist prescribers, suppliers and patients.